Pathology Grand Rounds

 Dec 05, 2022 @ 12:00 p.m.

Bahadir Yildiz, MD - Resident

Dr. Bahadir Yildiz will present 'Distance between tumor cells and the peritoneal surface to predict the risk of peritoneal metastases in colon cancer'.  There is accumulating data that the pT4a subcategory of colon cancer is diagnostically less straightforward than often assumed. I will talk about an article that was recently published that shows measurement of the distance between tumor cells and the peritoneal surface can be used to predict the risk of peritoneal metastases as well help in differentiating between T3 and T4a.

 Nov 07, 2022 @ 12:00 p.m.

Dr. Zhang will be presenting 'HER2-Low Breast Cancers - New Opportunities and Challenges' which reviews the history of HER2 in breast cancers, the evolving concept of HER2-low breast cancers, the current understanding of HER2-low breast cancers and the challenges and unanswered questions on HER2-low breast cancers.

 May 23, 2022 @ 12:00 p.m.

Dr. Benjamin Gertsen will be presenting 'Artificial Intelligence (AI) to Predict Cancer of Unknown Primary' about the details of Nature's first paper on computational pathology. The authors developed a deep-learning-based algorithm to predict tumors of unknown primary

 May 16, 2022 @ 12:00 p.m.

Dr. Kyla Jorgenson will be presenting 'Wischnewski spots: Hypothermia in the hospital'.  In the forensic community, multiple brown-black lesions seen in the stomach at autopsy have long been associated with hypothermia deaths and more recently with deaths due to diabetic ketoacidosis.  Anecdotal evidence and conjecture has lead to scientific experimentation to try to elucidate the underlying mechanism of these spots, however ultimately the answer is multifactorial in nature.  A hospital autopsy case is used to provide context for the current understanding in the literature with a look towards future avenues for research.

 May 09, 2022 @ 12:00 p.m.

'Molecular classification of DLBCL: Are we there yet? Will we ever be?'. Update on previous and future genetic and molecular classification systems for diffuse large B-cell lymphoma. Topics will include which methods have penetrated clinical practice, impacted patient care, and demonstrated significance in clinical trial design.

 Apr 25, 2022 @ 12:00 p.m.

'Recent advances in the molecular classification of round cell sarcomas' presented by Dr. Cristina Antonescu, Director, Bone & Soft Tissue Pathology, Memorial Sloan Kettering Cancer Center This talk will cover new molecular entities included in the 2020 WHO classification of soft tissue tumors, including: adamantinoma-like Ewing sarcoma, CIC-DUX4 sarcomas, BCOR-CCNB3 and BCOR ITD sarcomas.'Recent advances in the molecular classification of round cell sarcomas' presented by Dr. Cristina Antonescu, Director, Bone & Soft Tissue Pathology, Memorial Sloan Kettering Cancer Center This talk will cover new molecular entities included in the 2020 WHO classification of soft tissue tumors, including: adamantinoma-like Ewing sarcoma, CIC-DUX4 sarcomas, BCOR-CCNB3 and BCOR ITD sarcomas.

 Apr 04, 2022 @ 12:00 p.m.

'Hepatocellular carcinoma - diagnosis, prognosis, and staging', Dr. Xiaoyan Liao will be presenting her research work in hepatocellular carcinoma regarding cancer diagnosis, prognosis and staging.

 Mar 28, 2022 @ 12:00 p.m.

Dr. Goldman will be presenting 'Complement Activation in Human Myocardial Injury: Actor or Reactor?'. Actvation of the complement cascade has been identified in a variety of human mycardial diseases including transplantation associated injury, acute myocardial infarction, myocarditis, and sudden cardiac death. The significance of complement activation in these conditions likely varies withclinical context and is not completely understood.

 Mar 07, 2022 @ 12:00 p.m.

'Recent Developments for HER2-Low Breast Cancer' presented by Cansu Karakas, MD. Over the past two decades, the availability of HER2-targeted therapies has significantly improved clinical outcomes for patients with HER2-positive breast cancer. However, between 40%-50% of the patients have tumors with low HER2 expression for whom currently available HER2-targeted treatments have not proven effective. The unique mechanism and clinical benefits of newly developed Antibody Drug Conjugates have demonstrated substantial clinical antitumor acitivity with a manageable safety profile in patients with advanced/metastatic HER2-Low Breast Cancers.

'Contribution of Structural Biology to Vaccine Design: Can We Predict Our Way Out of the Next Pandemic?' presented by Chauncey Syposs, DO. This presentation is an update on his grand rounds on Alphafold from last year, as well as a discussion of some of the applications of this technology. Special presentation is paid to structural vaccinology. 

 Feb 14, 2022 @ 12:00 p.m.

Titia de Lange - Leon Hess Professor, The Rockefeller University

'Telomere shortening: Why and how' Human telomeres shorten progressively with cell divisions. This process ultimately leads to a proliferation barrier that has to be overcome during tumorigenesis. New data reveals how telomeres shorten and shows that telomere shortening is a powerful tumor suppressor pathway

 Feb 07, 2022 @ 12:00 p.m.

Aging Associated Changes in the Adult Human Skin Microbiome’ Presented by Tatsiana Pukhalskaya, MD. Aging Associated Changes in the Adult Human Skin Microbiome and the Host Factors That Affect Skin Microbiome Composition.

‘Molecular characterization and pathogenesis of gastrointestinal stromal tumor’ Presented by Juwairiya Arshi, MBBS. Presentation will be an update on the molecular genetics involved in the development and pathogenesis of Gastrointestinal tumor and different pathways involved.

 Jan 10, 2022 @ 12:00 p.m.

Mark Ettel, MD - Assistant Professor, Department of Pathology & Laboratory Medicine, University of Rochester Medical center

'Clinical Implications of Microscopic Colitis-Like Polyps' presented by Dr. Mark Ettel. Microscopic colitis (MC) is generally identified on random colon biopsies performed for chronic diarrhea, but rarely incidental polyps have histologic features of MC. I present data and results gathered from comparing patients with MC-like polyps to control patients with conventional polyps, as well as clinical implications regarding significance and management of these findings.

 Jan 03, 2022 @ 12:00 p.m.